Biotech

News

A new player in radioligand therapies, Actithera, has arrived on the scene with $75.5m in funding and lead FAP-targeted candidate for cancer.

Market Access

What were the major themes to come out of BIO Boston 2025? Despite global events in the background, a fair amount of positivity.

News

The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.

News

Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.

Oncology

Explore the latest advancements and challenges in ADC therapy at AACR 2025: New modalities and remaining challenges

News

Our round-up of recent biotech financings includes rounds for GRIN Therapeutics, GlycoEra, Syndeio, Juvenescence, and Vima Therapeutics.